Tariffs Dim Hologic's 2025 Expectations: Time to Reassess the Stock?

Women's health device maker, Hologic (HOLX) , slashed its earnings forecast for the full fiscal 2025, even as the latest second-quarter results topped expectations. The revenue target of $4.05-$4.10 billion remained the same as stated during the February earnings call, reflecting the $100 million cut from the initial guidance. The company cited pressures from U.S. tariffs and geopolitical uncertainties as key factors behind the revised guidance, with select divisional challenges also playing a part. Followi ...